Pacira Pharmaceuticals Inc. (NASDAQ:PCRX)‘s stock had its “market perform” rating restated by BMO Capital Markets in a research report issued to clients and investors on Saturday. They currently have a $35.00 target price on the stock. BMO Capital Markets’ price objective points to a potential upside of 6.54% from the company’s current price.
PCRX has been the subject of a number of other reports. Cowen and Company assumed coverage on Pacira Pharmaceuticals in a research note on Wednesday, September 7th. They set a “market perform” rating for the company. Zacks Investment Research raised Pacira Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $52.00 price objective for the company in a research note on Wednesday, August 10th. Mizuho reaffirmed a “buy” rating and set a $64.00 price objective on shares of Pacira Pharmaceuticals in a research note on Tuesday, August 2nd. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $81.00 price objective on shares of Pacira Pharmaceuticals in a research note on Wednesday, August 3rd. Finally, Brean Capital reaffirmed a “hold” rating on shares of Pacira Pharmaceuticals in a research note on Friday, August 5th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and seven have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $71.18.
Pacira Pharmaceuticals (NASDAQ:PCRX) traded up 1.23% during midday trading on Friday, hitting $32.85. The stock had a trading volume of 477,441 shares. Pacira Pharmaceuticals has a 52 week low of $30.25 and a 52 week high of $80.25. The firm’s market cap is $1.23 billion. The stock has a 50-day moving average of $34.21 and a 200-day moving average of $38.86.
Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its quarterly earnings data on Wednesday, November 2nd. The company reported $0.20 EPS for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.22. Pacira Pharmaceuticals had a negative return on equity of 1.52% and a negative net margin of 13.37%. The business earned $68.40 million during the quarter, compared to analysts’ expectations of $67.16 million. During the same period in the previous year, the firm earned $0.32 earnings per share. The firm’s quarterly revenue was up 10.0% compared to the same quarter last year. Analysts forecast that Pacira Pharmaceuticals will post $0.55 EPS for the current fiscal year.
Hedge funds have recently modified their holdings of the stock. FMR LLC raised its stake in shares of Pacira Pharmaceuticals by 19.1% in the second quarter. FMR LLC now owns 5,567,088 shares of the company’s stock worth $187,778,000 after buying an additional 892,511 shares during the period. Westfield Capital Management Co. LP raised its stake in Pacira Pharmaceuticals by 92.5% in the second quarter. Westfield Capital Management Co. LP now owns 1,333,868 shares of the company’s stock valued at $44,991,000 after buying an additional 640,814 shares during the last quarter. Schroder Investment Management Group bought a new stake in Pacira Pharmaceuticals during the second quarter valued at about $16,163,000. Peregrine Capital Management LLC bought a new stake in Pacira Pharmaceuticals during the third quarter valued at about $12,385,000. Finally, Point72 Asset Management L.P. bought a new stake in Pacira Pharmaceuticals during the second quarter valued at about $9,486,000.
About Pacira Pharmaceuticals